Scientists find how bacteria in cows milk may cause Crohn's disease

Liverpool, UK - 10 December 2007: Scientists at the University of Liverpool have found how a bacterium, known to cause illness in cattle, may cause Crohn's disease in humans.

Crohn's is a condition that affects one in 800 people in the UK and causes chronic intestinal inflammation, leading to pain, bleeding and diarrhoea.

The team found that a bacterium called Mycobacterium paratuberculosis releases a molecule that prevents a type of white blood cell from killing E.coli bacteria found in the body.  E.coli is known to be present within Crohn’s disease tissue in increased numbers.

It is thought that the Mycobacteria make their way into the body’s system via cows’ milk and other dairy products.  In cattle it can cause an illness called Johne's disease - a wasting, diarrhoeal condition. Until now, however, it has been unclear how this bacterium could trigger intestinal inflammation in humans.

Professor Jon Rhodes, from the University’s School of Clinical Sciences, explains: “Mycobacterium paratuberculosis has been found within Crohn’s disease tissue but there has been much controversy concerning its role in the disease.  We have now shown that these Mycobacteria release a complex molecule containing a sugar, called mannose.  This molecule prevents a type of white blood cells, called macrophages, from killing internalised E.Coli.” 

Scientists have previously shown that people with Crohn’s disease have increased numbers of a ‘sticky’ type of E.coli and weakened ability to fight off intestinal bacteria.  The suppressive effect of the Mycobacterial molecule on this type of white blood cell suggests it is a likely mechanism for weakening the body’s defence against the bacteria.

Professor Rhodes added: "We also found that this bacterium is a likely trigger for a circulating antibody protein (ASCA) that is found in about two thirds of patients with Crohn's disease, suggesting that these people may have been infected by the Mycobacterium."

The team is beginning clinical trials to assess whether an antibiotic combination can be used to target the bacteria contained in white blood cells as a possible treatment for Crohn’s disease.

The research was funded by Core and the Medical Research Council and is published in Gastroenterology.

Notes to editors:

1.  The University of Liverpool is one of the UK's leading research institutions.  It attracts collaborative and contract research commissions from a wide range of national and international organisations valued at more than £100 million annually.
For further information:

For further information, contact:

Kate Spark
Media Relations Manager
+44 (0) 151 794 2247
(out of hours +44 (0) 7970 247391)
kate.spark@liv.ac.uk

Samantha Martin
Senior Press Officer
+44 (0) 151 794 2248
(out of hours +44 (0) 7973 247836)
samantha.martin@liv.ac.uk

Charlotte Roberts
Press Officer
+44 (0) 151 794 3044
(out of hours +44 (0) 7970 247396)
charlotte.roberts@liverpool.ac.uk

Laura Johnson
Press Officer
+44 (0) 151 792 2026
(out of hours +44 (0) 7807 106562)
laura.johnson@liverpool.ac.uk